Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity

Detalhes bibliográficos
Autor(a) principal: Alvares,Ronaldo A.
Data de Publicação: 2010
Outros Autores: Silva,Jose A. F., Barboza,Andre L., Monteiro,Raphael T. M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000600012
Resumo: PURPOSE: To evaluate the efficacy of botulinum toxin type A injections in the detrusor muscle in patients with spinal cord injury and urinary incontinence due to detrusor overactivity and refractory to anticholinergic agents. MATERIALS AND METHODS: We prospectively evaluated 22 patients with spinal cord injuries, whose bladders were emptied by intermittent catheterization. All patients had detrusor overactivity and urinary incontinence that proved difficult to treat, despite using high doses of two different anticholinergics. The pre-treatment assessment included a complete urodynamic study and ultrasonography of the kidneys and urinary tract. A one-month follow-up was completed with urodynamic evaluation and the clinical response was evaluated through outpatient consultations and telephone contact. RESULTS: After the procedure, the maximum cystometric capacity and the bladder reflex volume increased, whereas the maximum detrusor pressure and compliance decreased. The mean duration of continence was 7 ± 7 months. In 18 patients (81.8%), it was necessary to administer anticholinergics to achieve continence. Five patients (22.7%) had indication of reinjection, and augmentation cystoplasty was indicated in 9 patients (40.9%). CONCLUSION: The use of botulinum toxin in the treatment of neurogenic detrusor overactivity refractory to anticholinergics is an option before more invasive treatments, such as augmentation cystoplasty, are attempted. In our study as well as in the literature, there was improvement in most urodynamic parameters. Overall, 40.9% of patients underwent augmentation cystoplasty and 81.8% of patients needed anticholinergic agents to reach urinary continence. Further studies are necessary to improve the procedure and to achieve better clinical results.
id SBU-1_a54b29fecc62a37842714117c0027350
oai_identifier_str oai:scielo:S1677-55382010000600012
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivityneurogenic bladderspinal cord injurybotulinum toxin Aanticholinergic refractoryPURPOSE: To evaluate the efficacy of botulinum toxin type A injections in the detrusor muscle in patients with spinal cord injury and urinary incontinence due to detrusor overactivity and refractory to anticholinergic agents. MATERIALS AND METHODS: We prospectively evaluated 22 patients with spinal cord injuries, whose bladders were emptied by intermittent catheterization. All patients had detrusor overactivity and urinary incontinence that proved difficult to treat, despite using high doses of two different anticholinergics. The pre-treatment assessment included a complete urodynamic study and ultrasonography of the kidneys and urinary tract. A one-month follow-up was completed with urodynamic evaluation and the clinical response was evaluated through outpatient consultations and telephone contact. RESULTS: After the procedure, the maximum cystometric capacity and the bladder reflex volume increased, whereas the maximum detrusor pressure and compliance decreased. The mean duration of continence was 7 ± 7 months. In 18 patients (81.8%), it was necessary to administer anticholinergics to achieve continence. Five patients (22.7%) had indication of reinjection, and augmentation cystoplasty was indicated in 9 patients (40.9%). CONCLUSION: The use of botulinum toxin in the treatment of neurogenic detrusor overactivity refractory to anticholinergics is an option before more invasive treatments, such as augmentation cystoplasty, are attempted. In our study as well as in the literature, there was improvement in most urodynamic parameters. Overall, 40.9% of patients underwent augmentation cystoplasty and 81.8% of patients needed anticholinergic agents to reach urinary continence. Further studies are necessary to improve the procedure and to achieve better clinical results.Sociedade Brasileira de Urologia2010-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000600012International braz j urol v.36 n.6 2010reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/S1677-55382010000600012info:eu-repo/semantics/openAccessAlvares,Ronaldo A.Silva,Jose A. F.Barboza,Andre L.Monteiro,Raphael T. M.eng2011-03-23T00:00:00Zoai:scielo:S1677-55382010000600012Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2011-03-23T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity
title Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity
spellingShingle Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity
Alvares,Ronaldo A.
neurogenic bladder
spinal cord injury
botulinum toxin A
anticholinergic refractory
title_short Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity
title_full Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity
title_fullStr Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity
title_full_unstemmed Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity
title_sort Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity
author Alvares,Ronaldo A.
author_facet Alvares,Ronaldo A.
Silva,Jose A. F.
Barboza,Andre L.
Monteiro,Raphael T. M.
author_role author
author2 Silva,Jose A. F.
Barboza,Andre L.
Monteiro,Raphael T. M.
author2_role author
author
author
dc.contributor.author.fl_str_mv Alvares,Ronaldo A.
Silva,Jose A. F.
Barboza,Andre L.
Monteiro,Raphael T. M.
dc.subject.por.fl_str_mv neurogenic bladder
spinal cord injury
botulinum toxin A
anticholinergic refractory
topic neurogenic bladder
spinal cord injury
botulinum toxin A
anticholinergic refractory
description PURPOSE: To evaluate the efficacy of botulinum toxin type A injections in the detrusor muscle in patients with spinal cord injury and urinary incontinence due to detrusor overactivity and refractory to anticholinergic agents. MATERIALS AND METHODS: We prospectively evaluated 22 patients with spinal cord injuries, whose bladders were emptied by intermittent catheterization. All patients had detrusor overactivity and urinary incontinence that proved difficult to treat, despite using high doses of two different anticholinergics. The pre-treatment assessment included a complete urodynamic study and ultrasonography of the kidneys and urinary tract. A one-month follow-up was completed with urodynamic evaluation and the clinical response was evaluated through outpatient consultations and telephone contact. RESULTS: After the procedure, the maximum cystometric capacity and the bladder reflex volume increased, whereas the maximum detrusor pressure and compliance decreased. The mean duration of continence was 7 ± 7 months. In 18 patients (81.8%), it was necessary to administer anticholinergics to achieve continence. Five patients (22.7%) had indication of reinjection, and augmentation cystoplasty was indicated in 9 patients (40.9%). CONCLUSION: The use of botulinum toxin in the treatment of neurogenic detrusor overactivity refractory to anticholinergics is an option before more invasive treatments, such as augmentation cystoplasty, are attempted. In our study as well as in the literature, there was improvement in most urodynamic parameters. Overall, 40.9% of patients underwent augmentation cystoplasty and 81.8% of patients needed anticholinergic agents to reach urinary continence. Further studies are necessary to improve the procedure and to achieve better clinical results.
publishDate 2010
dc.date.none.fl_str_mv 2010-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000600012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000600012
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S1677-55382010000600012
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.36 n.6 2010
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318071968432128